Dolby Laboratories, Inc. vs Moderna, Inc. — how do they compare? Dolby Laboratories, Inc. trades at $60.9 (market cap $5.75B), while Moderna, Inc. trades at $60.45 (market cap $24.18B). The key difference: Moderna, Inc. is far larger — about 4.2× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays a 2.35% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| DLB | MRNA | |
|---|---|---|
Market Cap | $5.75B | $24.18B |
Sector | Industrials | Health |
52-Week High | $75.62 | $81.80 |
52-Week Low | $48.51 | $22.36 |
Enterprise Value | $5.12B | $20.33B |
Dividend Yield | 2.35% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Moderna (MRNA) trades at $59.81, up 1.08% today, with a bullish technical signal from moving averages and recent FDA approval for its mRNA flu vaccine mFLUSIVA. Despite beating Q2 2026 EPS estimates, revenue has declined from pandemic peaks, with a net income margin of -142.58% in 2026. The stock faces resistance near $61-$63, while support lies at $56-$59.
Outlook remains mixed; pipeline advancements in flu, Ebola, and oncology offer growth potential, but persistent losses and high valuation ratios pose risks. Analyst consensus is cautious with a $54.33 price target below current levels, reflecting concerns over profitability amid transitioning business focus.
Trailing returns across standard periods
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →